Premium
Resveratrol in metabolic health: an overview of the current evidence and perspectives
Author(s) -
Poulsen Morten Møller,
Jørgensen Jens Otto Lunde,
Jessen Niels,
Richelsen Bjørn,
Pedersen Steen Bønløkke
Publication year - 2013
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12141
Subject(s) - resveratrol , calorie restriction , nonalcoholic fatty liver disease , clinical trial , inflammation , medicine , disease , bioinformatics , pharmacology , biology , fatty liver
In the search for novel preventive and therapeutic modalities in the management of metabolic diseases and obesity, resveratrol has attracted great attention over the past decades. Preclinical trials suggest that resveratrol mimics the metabolic effects of calorie restriction (CR) via activation of silent mating type information regulation 2 homolog 1 (SIRT1). In experimental animals, this potential translates into prevention or improvement of glucose metabolism, anti‐inflammation, cancer, and nonalcoholic fatty liver disease. Moreover, and in accordance with CR, supplementation with resveratrol promotes longevity in several primitive species and protects against diet‐induced metabolic abnormalities in rodents. Despite the substantial preclinical evidence, human clinical data are very scarce, and even though the compound is widely distributed as an over‐the‐counter human nutritional supplement, its therapeutic rationale has not been well characterized. In this review, we provide a brief overview of the field and discuss the future scientific directions of resveratrol research.